Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 10, 2010, Pages 4098-4106

  Van Rensburg, Dirkie J J ^a   Perng, Reury Perng ^b   Mitha, Ismail H ^c   Bester, Andrè J ^d   Kasumba, Joseph ^e   Wu, Ren Guang ^f   Ho, Ming Lin ^g   Chang, Li Wen ^h   Chung, David T ^h   Chang, Yu Ting ^h   King, Chi Hsin R ^h   Hsu, Ming Chu ^h  

^a Park Medical Center   (South Africa)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c Benmed/Pentagon Hospital   (South Africa)

^d Jubilee Hospital   (South Africa)

^e JOSHA Research   (South Africa)

^f CHENG CHING GENERAL HOSPITAL   (Taiwan)

^g CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^h TaiGen Biotechnology Co Ltd   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; NEMONOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANEMIA; ANTIBACTERIAL ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; LEGIONELLA PNEUMOPHILA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOPLASMA PNEUMONIAE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTI-BACTERIAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; PNEUMONIA; QUINOLONES; TREATMENT OUTCOME;

EID: 77957351208     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00295-10     Document Type: Article

References (35)

1. Adam, H. J., N. M. Laing, C. R. King, B. Lulashnyk, D. J. Hoban, and G. G. Zhanel. 2009. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. Antimicrob. Agents Chemother. 53:4915-4920.
2. Bochud, P. Y., F. Moser, P. Erard, F. Verdon, J. P. Studer, G. Villard, A. Cosendai, M. Cotting, F. Heim, J. Tissot, Y. Strub, M. Pazeller, L. Saghafi, A. Wenger, D. Germann, L. Matter, J. Bille, L. Pfister, and P. Francioli. 2001. Community-acquired pneumonia. A prospective outpatient study. Medicine (Baltimore) 80:75-87.
3. British Thoracic Society Standards of Care Committee. 2001. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 56(Suppl. 4):iv1-iv64.
4. Carbonara, S., L. Monno, B. Longo, and G. Angarano. 2009. Community-acquired pneumonia. Curr. Opin. Pulm. Med. 15:261-273.
5. Chen, S. J., L. Lin, and L. W. Chang. 2007. Analysis of antibacterial response of nemonoxacin (TG-873870) against major pathogens from respiratory tract and skin infections, abstr. 441. Abstr. 45th Infect. Dis. Soc. Am.
6. Chen, Y. H., C. Y. Liu, J. J. Lu, C. H. King, and P. R. Hsueh. 2009. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan. J. Antimicrob. Chemother. 64:1226-1229.
7. Chung, D. T., C. Y. Tsai, S. J. Chen, L. W. Chang, C. H. King, C. H. Hsu, K. M. Chiu, H. C. Tan, Y. T. Chang, and M. C. Hsu. 2010. Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. Antimicrob. Agents Chemother. 54:411-417.
8. Falguera, M., O. Sacristán, A. Nogués, A. Ruiz-González, M. Garcia, A. Manonelles, and M. Rubio-Caballero. 2001. Nonsevere community-acquired pneumonia: correlation between cause and severity or comorbidity. Arch. Intern. Med. 161:1866-1872.
9. File, T. M., Jr. 2006. Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia. Clin. Microbiol. Infect. 12(Suppl. 3):31-41.
10. Fine, M. J., M. A. Smith, C. A. Carson, S. S. Mutha, S. S. Sankey, L. A. Weissfeld, and W. N. Kapoor. 1996. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 275:134-141.
11. Greenberg, R. N. 1984. Overview of patient compliance with medication dosing: a literature review. Clin. Ther. 6:592-599.
12. Ho, P. L., V. C. Cheng, and C. M. Chu. 2009. Antibiotic resistance in community-acquired pneumonia caused by Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, and Acinetobacter baumannii. Chest 136:1119-1127.
13. Hsu, C. H., L. Lin, R. Leunk, and D. Reichart. 2008. In vivo efficacy of nemonoxacin in a mouse protection model, abstr. B-1005. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
14. Hsu, C. H., L. Lin, R. Leunk, and D. Reichart. 2008. In vivo efficacy of nemonoxacin in a mouse pulmonary infection model, abstr. B-056. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
15. Infectious Diseases Society of America. 2008. Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia. Clin. Infect. Dis. 47(Suppl. 3):S249-S265.
16. Jackson, M. L., K. M. Neuzil, W. W. Thompson, D. K. Shay, O. Yu, C. A. Hanson, and L. A. Jackson. 2004. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin. Infect. Dis. 39:1642-1650.
17. King, C. H. R., L. Lin, and R. Leunk. 2008. In vitro resistance development to nemonoxacin for Streptococcus pneumoniae, abstr. C1-1971. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
18. Lai, C. C., C. K. Tan, S. H. Lin, C. H. Liao, C. H. Chou, H. L. Hsu, Y. T. Huang, and P. R. Hsueh. 2009. Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species. J. Antimicrob. Chemother. 64:73-78.
19. Lauderdale, T. L., Y. R. Shiau, J. F. Lai, H. C. Chen, and C. H. King. 2007. In vitro antibacterial activity of nemonoxacin (TG-873870), a new nonfluorinated quinolone, against clinical isolates, abstr. E-1635. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL. American Society for Microbiology, Washington, DC.
20. Leophonte, P., T. File, and C. Feldman. 2004. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir. Med. 98:708-720.
21. Lin, L., L.-W. Chang, C.-Y. Tsai, C.-H. Hsu, D. T. Chung, W. S. Aronstein, F. Ajayi, B. Kuzmak, and R. A. Lyon. 2010. Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. Antimicrob. Agents Chemother. 54:405-410.
22. Low, D. E. 2009. Fluoroquinolones for treatment of community-acquired pneumonia and tuberculosis: putting the risk of resistance into perspective. Clin. Infect. Dis. 48:1361-1363.
23. Mandell, L. A. 2008. Spectrum of microbial etiology of community-acquired pneumonia in hospitalized patients: implications for selection of the population for enrollment in clinical trials. Clin. Infect. Dis. 47(Suppl. 3):S189-S192.
24. Mandell, L. A., R. G. Wunderink, A. Anzueto, J. G. Bartlett, G. D. Campbell, N. C. Dean, S. F. Dowell, T. M. File, Jr., D. M. Musher, M. S. Niederman, A. Torres, and C. G. Whitney. 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2):S27-S72.
25. National Center for Health Statistics. 2008. Health, United States, with special feature on the health of young adults. http://www.cdc.gov/nchs/data/hus/ hus08.pdf.
26. Niederman, M. S. 2007. Recent advances in community-acquired pneumonia: inpatient and outpatient. Chest 131:1205-1215. (Pubitemid 46608726)
27. Pan, X. S., J. Ambler, S. Mehtar, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.
28. Pankuch, G. A., K. Kosowska-Shick, P. McGhee, C. H. R. King, and P. C. Appelbaum. 2008. Comparative antistaphylococcal activity of nemonoxacin, a novel broad-spectrum quinolone, abstr. C1-189. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
29. Restrepo, M. I., E. M. Mortensen, J. A. Velez, C. Frei, and A. Anzueto. 2008. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest 133:610-617. (Pubitemid 351367367)
30. Ruiz, M., S. Ewig, M. A. Marcos, J. A. Martinez, F. Arancibia, J. Mensa, and A. Torres. 1999. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am. J. Respir. Crit. Care Med. 160:397-405.
31. Song, J. H., W. S. Oh, C. I. Kang, D. R. Chung, K. R. Peck, K. S. Ko, J. S. Yeom, C. K. Kim, S. W. Kim, H. H. Chang, Y. S. Kim, S. I. Jung, Z. Tong, Q. Wang, S. G. Huang, J. W. Liu, M. K. Lalitha, B. H. Tan, P. H. Van, C. C. Carlos, T. So, and the Asian Network for Surveillance of Resistant Pathogens Study Group. 2008. Epidemiology and clinical outcomes of communityacquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. Int. J. Antimicrob. Agents. 31:107-114.
32. Tan, C.-K., C.-C. Lai, C.-H. Liao, C.-H. Chou, H.-L. Hsu, Y.-T. Huang, and P.-R. Hsueh. 2009. Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 64:428-429.
33. Tanaseanu, C., S. Milutinovic, P. I. Calistru, J. Strausz, M. Zolubas, V. Chernyak, N. Dartois, N. Castaing, H. Gandjini, and C. A. Cooper. 2009. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm. Med. 9:44.
34. Tsang, K. W., and T. M. File, Jr. 2008. Respiratory infections unique to Asia. Respirology 13:937-949.
35. Woodhead, M. 2002. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur. Respir. J. Suppl. 36:20s-27s.